A Phase 2 interventional study of DS-8201a in Breast Cancer, sponsored by Daiichi Sankyo. Terminated at 99 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 33 in phase 2, and was the 1st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
24 studies in Breast Neoplasms by Daiichi Sankyo: 6 open now, 8 under way, 3 of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2017, is one of 3 in phase 2, and was the 4th registered.
Daiichi Sankyo’s Breast Neoplasms studies by the year they started, since 1999.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among Daiichi Sankyo’s 24 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has documented breast cancer that:
Exclusion Criteria:
Has history of any disease, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
Drug: DS-8201a
T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
Drug: DS-8201a
T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
Drug: DS-8201a
In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
Drug: DS-8201a
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Also known as: Experimental product
Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
The number of participants with objective response was assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment, by independent central imaging facility review based on RECIST version 1.1.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Objective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
The number of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment. Investigator-assessed objective response rate (ORR) was defined as the proportion of participants who achieved a best overall response of complete response or partial response based on local radiologists/investigators' tumor assessments.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Best Overall Tumor Response as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
Best overall tumor response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by the investigator based on RECIST v1.1. Participants who were non-evaluable (NE) are also reported.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Disease Control Rate and Clinical Benefit Rate as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
Number of participants with controlled disease and who received clinical benefit from treatment as assessed by independent central review. DCR was defined as the proportion of participants who achieved a best overall response of complete response, partial response, or stable disease. CBR was defined as the proportion of participants who achieved a best overall response of complete response or partial response or more than 6 months of stable disease.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Duration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
The estimated duration of confirmed response (complete response \[CR\] or partial response \[PR\]) was assessed by independent central review. Duration of response was defined as the time interval between the date of first documentation of objective response (CR or PR) and the date of the first objective documentation of disease progression or death due to any cause.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Progression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
The point estimate of progression-free survival (PFS) is reported. PFS was defined as the time interval between the date of randomization/registration and the first documentation of disease progression or death due to any cause.
Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Percent Change From Baseline in Sum of Diameters Over Time as Determined by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
Best percent change in sum of diameters of measurable tumors was based on RECIST 1.1. The best percent change was defined as the percent change in the smallest sum of diameters from all post-baseline tumor assessments, taking as reference the baseline sum of diameters.
Time frame: Baseline up to Week 6, 12, 18, 24, 30, 36 post dose
Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Safety Analysis Set)
TEAEs were assessed by severity and seriousness according to unique criteria. Severity described the intensity of an event and was graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; and Grade 5: Death related to AE. Serious TEAEs were defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization, or causes prolongation of existing hospitalization.
Time frame: Day 0 to Day 47 post last dose
Participants who met all of the inclusion and none of the exclusion criteria were enrolled and randomized to treatment (Part 1) or received DS-8201a at the recommended dose (Part 2).
| Milestone | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose |
|---|---|---|---|---|---|
| Started | 50 | 48 | 21 | 130 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 50 | 48 | 21 | 130 | 4 |
| Withdrew: Progressive disease | 24 | 23 | 11 | 66 | 1 |
| Withdrew: Adverse event | 14 | 13 | 9 | 22 | 2 |
| Withdrew: Withdrawal by subject | 5 | 4 | 0 | 8 | 1 |
| Withdrew: Physician decision | 1 | 1 | 1 | 7 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 6 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 1 | 0 | 7 | 0 |
| Withdrew: Other | 2 | 5 | 0 | 14 | 0 |
The number of participants with objective response was assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment, by independent central imaging facility review based on RECIST version 1.1.
| Participants | Part 1 and Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|
| Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set) | 109 | 111 |
The number of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment. Investigator-assessed objective response rate (ORR) was defined as the proportion of participants who achieved a best overall response of complete response or partial response based on local radiologists/investigators' tumor assessments.
| Participants | Part 1 and Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose |
|---|---|---|---|---|
| Objective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set) | 116 | 118 | 37 | 18 |
Best overall tumor response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by the investigator based on RECIST v1.1. Participants who were non-evaluable (NE) are also reported.
| Participants | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 1 + Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|---|---|
| Complete response | 3 | 0 | 4 | 6 |
| Partial response | 34 | 18 | 112 | 112 |
| Stable disease | 10 | 3 | 59 | 61 |
| Progressive disease | 0 | 0 | 4 | 4 |
| Non-evaluable | 1 | 0 | 1 | 1 |
Number of participants with controlled disease and who received clinical benefit from treatment as assessed by independent central review. DCR was defined as the proportion of participants who achieved a best overall response of complete response, partial response, or stable disease. CBR was defined as the proportion of participants who achieved a best overall response of complete response or partial response or more than 6 months of stable disease.
| Participants | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 1 + Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|---|---|
| Disease control rate | 47 | 21 | 175 | 179 |
| Clinical benefit rate | 41 | 20 | 127 | 130 |
The estimated duration of confirmed response (complete response \[CR\] or partial response \[PR\]) was assessed by independent central review. Duration of response was defined as the time interval between the date of first documentation of objective response (CR or PR) and the date of the first objective documentation of disease progression or death due to any cause.
| months | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 1 + Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|---|---|
| Duration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set) | NA (8.3 to NA) | 6.0 (4.8 to 8.3) | NA (NA to NA) | NA (NA to NA) |
The point estimate of progression-free survival (PFS) is reported. PFS was defined as the time interval between the date of randomization/registration and the first documentation of disease progression or death due to any cause.
| months | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 1 + Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|---|---|
| Progression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set) | NA (NA to NA) | 9.5 (7.4 to 13.2) | NA (10.6 to NA) | NA (10.6 to NA) |
Best percent change in sum of diameters of measurable tumors was based on RECIST 1.1. The best percent change was defined as the percent change in the smallest sum of diameters from all post-baseline tumor assessments, taking as reference the baseline sum of diameters.
| Percent change from baseline | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 1 + Part 2a: DS-8201a Low Dose | Part 1 + Part 2a + Part 2b: DS-8201a Low Dose |
|---|---|---|---|---|
| Baseline to Week 6 | -26.2 ± 18.3 | -32.9 ± 25.4 | -26.9 ± 21.6 | -26.9 ± 22.5 |
| Baseline to Week 12 | -39.6 ± 22.7 | -43.6 ± 28.1 | -39.9 ± 24.5 | -40.1 ± 24.9 |
| Baseline to Week 18 | -50.1 ± 22.1 | -58.5 ± 29.4 | -44.4 ± 27.8 | -44.9 ± 28.0 |
| Baseline to Week 24 | -56.3 ± 22.1 | -61.9 ± 32.0 | -49.2 ± 30.6 | -49.3 ± 30.5 |
| Baseline to Week 30 | -59.1 ± 26.1 | -63.9 ± 32.2 | -51.2 ± 29.2 | -51.5 ± 29.2 |
| Baseline to Week 36 | -61.0 ± 26.7 | -54.6 ± 32.2 | -55.5 ± 29.9 | -55.5 ± 29.9 |
| Best percent change from baseline | -59.5 ± 28.2 | -65.3 ± 27.7 | -50.5 ± 28.3 | -50.6 ± 28.8 |
TEAEs were assessed by severity and seriousness according to unique criteria. Severity described the intensity of an event and was graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; and Grade 5: Death related to AE. Serious TEAEs were defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization, or causes prolongation of existing hospitalization.
| Participants | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose |
|---|---|---|---|---|---|
| Any TEAE | 50 | 48 | 21 | 129 | 4 |
| Drug-related TEAEs | 50 | 47 | 21 | 128 | 4 |
| Drug-related TEAEs of CTCAE ≥Grade 3 | 26 | 32 | 16 | 48 | 3 |
| Any serious TEAE | 11 | 6 | 8 | 25 | 0 |
| Drug-related serious TEAEs | 6 | 4 | 5 | 10 | 0 |
| TEAEs associated with drug discontinuation | 6 | 6 | 8 | 8 | 1 |
| Related TEAEs associated with drug discontinuation | 6 | 6 | 8 | 7 | 1 |
| TEAEs associated with dose reduction | 13 | 19 | 11 | 21 | 3 |
| Drug-related TEAEs associated with dose reduction | 11 | 18 | 11 | 20 | 3 |
| TEAEs associated with dose interruption | 19 | 16 | 12 | 36 | 2 |
| Related TEAEs associated with drug interruption | 17 | 13 | 11 | 29 | 2 |
| TEAEs associated with death | 1 | 1 | 2 | 8 | 0 |
| Drug-related TEAEs associated with death | 0 | 0 | 1 | 2 | 0 |
Collected over Adverse event (AE) data were collected from Day 0 through Day 47 post last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: DS-8201a Low Dose | 33/50 (66%) | 14/50 (28%) | 50/50 (100%) |
| Part 1: DS-8201a Medium Dose | 30/48 (62.5%) | 11/48 (22.9%) | 48/48 (100%) |
| Part 1: DS-8201a High Dose | 18/21 (85.7%) | 8/21 (38.1%) | 21/21 (100%) |
| Part 2a: DS-8201a Low Dose | 86/130 (66.2%) | 42/130 (32.3%) | 129/130 (99.2%) |
| Part 2b (Exploratory): DS-8201a Low Dose | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| Event | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose |
|---|---|---|---|---|---|
| PneumonitisInfections and infestations | 1/50 | 1/48 | 1/21 | 3/130 | 1/4 |
| COVID-19 pneumoniaInfections and infestations | 0/50 | 0/48 | 0/21 | 0/130 | 1/4 |
| Post procedural complicationInjury, poisoning and procedural complications | 0/50 | 0/48 | 0/21 | 0/130 | 1/4 |
| Femur fractureInjury, poisoning and procedural complications | 0/50 | 0/48 | 0/21 | 0/130 | 1/4 |
| Alanine aminotransferase increasedInvestigations | 0/50 | 0/48 | 2/21 | 0/130 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 0/50 | 0/48 | 2/21 | 0/130 | 0/4 |
| NauseaGastrointestinal disorders | 0/50 | 3/48 | 0/21 | 3/130 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 3/50 | 0/48 | 0/21 | 0/130 | 0/4 |
| CellulitisInfections and infestations | 3/50 | 0/48 | 0/21 | 1/130 | 0/4 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/50 | 0/48 | 1/21 | 0/130 | 0/4 |
| Event | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 38/50 | 40/48 | 13/21 | 102/130 | 3/4 |
| Neutrophil count decreasedInvestigations | 16/50 | 19/48 | 13/21 | 25/130 | 0/4 |
| White blood cell count decreasedInvestigations | 14/50 | 17/48 | 13/21 | 22/130 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 25/50 | 29/48 | 8/21 | 62/130 | 2/4 |
| FatigueGeneral disorders | 22/50 | 25/48 | 11/21 | 70/130 | 2/4 |
| VomitingGastrointestinal disorders | 23/50 | 21/48 | 8/21 | 61/130 | 2/4 |
| StomatitisGastrointestinal disorders | 12/50 | 16/48 | 4/21 | 17/130 | 2/4 |
| Odema peripheralGeneral disorders | 4/50 | 8/48 | 0/21 | 13/130 | 2/4 |
| HeadacheNervous system disorders | 8/50 | 13/48 | 2/21 | 32/130 | 2/4 |
| ConstipationGastrointestinal disorders | 16/50 | 19/48 | 10/21 | 50/130 | 1/4 |
| Age, Categorical(Participants) | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 33 | 16 | 101 | 4 | 189 |
| >=65 years | 15 | 15 | 5 | 29 | 0 | 64 |
| Age, Continuous(years) | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose | Total |
|---|---|---|---|---|---|---|
| Mean | 57.9 ± 11.3 | 55.8 ± 13.0 | 54.4 ± 10.5 | 55.4 ± 11.9 | 49.8 ± 9.2 | 55.8 ± 11.8 |
| Sex: Female, Male(Participants) | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose | Total |
|---|---|---|---|---|---|---|
| Female | 50 | 48 | 21 | 130 | 4 | 253 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 | 2 |
| Asian | 22 | 22 | 12 | 47 | 1 | 104 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 0 | 1 | 1 | 1 | 5 |
| White | 24 | 23 | 8 | 76 | 1 | 132 |
| More than one race | 1 | 1 | 0 | 2 | 0 | 4 |
| Unknown or Not Reported | 0 | 1 | 0 | 4 | 0 | 5 |
| Region of Enrollment(participants) | Part 1: DS-8201a Low Dose | Part 1: DS-8201a Medium Dose | Part 1: DS-8201a High Dose | Part 2a: DS-8201a Low Dose | Part 2b (Exploratory): DS-8201a Low Dose | Total |
|---|---|---|---|---|---|---|
| South Korea | 7 | 7 | 0 | 25 | 1 | 40 |
| Belgium | 0 | 2 | 0 | 7 | 0 | 9 |
| United States | 15 | 14 | 10 | 36 | 2 | 77 |
| Japan | 16 | 15 | 11 | 14 | 0 | 56 |
| Italy | 0 | 1 | 0 | 8 | 1 | 10 |
| United Kingdom | 0 | 0 | 0 | 12 | 0 | 12 |
| France | 2 | 1 | 0 | 17 | 0 | 20 |
| Spain | 10 | 8 | 0 | 11 | 0 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Aug 2017 to primary completion in Mar 2019, 18 months.
Results were first posted in Feb 2020, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan